4.5 Review

Zinc and zinc transporters in prostate carcinogenesis

期刊

NATURE REVIEWS UROLOGY
卷 10, 期 4, 页码 219-226

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nrurol.2013.43

关键词

-

资金

  1. NCI NIH HHS [R01 CA134463, R03 CA167671, P30 CA006927] Funding Source: Medline

向作者/读者索取更多资源

The healthy human prostate accumulates the highest level of zinc of any soft tissue in the body. This unique property is retained in BPH, but is lost in prostatic malignancy, which implicates changes in zinc and its transporters in carcinogenesis. Indeed, zinc concentrations diminish early in the course of prostate carcinogenesis, preceding histopathological changes, and continue to decline during progression toward castration-resistant disease. Numerous studies suggest that increased zinc intake might protect against progression of prostatic malignancy. In spite of increased dietary intake, zinc accumulation might be limited by the diminished expression of zinc uptake transporters, resulting in decreased intratumoural zinc levels. This finding can explain the conflicting results of various epidemiological studies evaluating the role of zinc supplementation on primary and secondary prostate cancer prevention. Overall, more research into the mechanisms of zinc homeostasis are needed to fully understand its impact on prostate carcinogenesis. Only then can the potential of zinc and zinc transport proteins be harnessed in the diagnosis and treatment of men with prostate cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Long-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue-Sparing Intensity-Modulated Radiation Therapy for Men With Clinically Localized Prostate Cancer

Eddie Zhang, Karen J. Ruth, Mark K. Buyyounouski, Robert A. Price Jr, Robert G. Uzzo, Mark L. Sobczak, Alan Pollack, J. . Karen Wong, David Y. T. Chen, Mark A. Hallman, Richard E. Greenberg, Deborah Watkins-Bruner, Tahseen Al-Saleem, Eric M. Horwitz

Summary: This study aimed to compare the preservation of erectile function between limiting the doses delivered to the penile bulb and corporal bodies with intensity modulated radiation therapy (IMRT) and standard IMRT in men with prostate cancer. The results showed that there was no significant difference in the preservation of erectile function between the two treatment methods.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Letter Oncology

What's in a Name: An Analysis of Gender-Based Acronyms in Clinical Trials

Laura Bukavina, Mohit Sindhani, Shreyas S. Joshi, Elizabeth Plimack, Andres Correa, Nicole Uzzo, Alexander Kutikov, Robert Uzzo

ANNALS OF SURGICAL ONCOLOGY (2023)

Article Oncology

Impact of Variant Histology on Oncological Outcomes in Upper Tract Urothelial Carcinoma: Results From the ROBUUST Collabo rative Group

Antoin Douglawi, Alireza Ghoreifi, Umberto Carbonara, Wesley Yip, Robert G. Uzzo, Vitaly Margulis, Matteo Ferro, Ottavio De Cobelli, Zhenjie Wu, Giuseppe Simone, Riccardo Mastroianni, Koon H. Rha, Daniel D. Eun, Adam C. Reese, James R. Porter, Ithaar Derweesh, Reza Mehrazin, Giuseppe Rosiello, Riccardo Tellini, Marcus Jamil, Alexander Kenigsberg, Jason M. Farrow, William P. Schrock, Giovanni Cacciamani, Abhishek Srivastava, Amit S. Bhattu, Alexandre Mottrie, Mark L. Gonzalgo, Chandru P. Sundaram, Firas Abdollah, Andrea Minervini, Riccardo Autorino, Hooman Djaladat

Summary: This study retrospectively analyzed data of UTUC patients who underwent RNU and found that VH was associated with increased risk of metastasis and death.

CLINICAL GENITOURINARY CANCER (2023)

Article Oncology

Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis

Laura Bukavina, Spencer Bell, Vignesh T. Packiam, Marc Smaldone, Philip Abbosh, Robert Uzzo, Alexander Kutikov, Andres F. Correa, Diana E. Magee

Summary: This study evaluated the cost effectiveness of BCG compared to sequential gemcitabine-docetaxel in high-risk NMIBC patients. The results showed that gemcitabine-docetaxel had similar effectiveness but lower cost than BCG, making it a potential alternative as a first-line intravesical therapy.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2023)

Article Oncology

Distinguishing lipid-poor angiomyolipoma from renal carcinoma using tumor shape

Marshall Strother, Robert N. Uzzo, Elizabeth Handorf, Robert G. Uzzo

Summary: The study aimed to validate the overflowing beer sign (OBS) for distinguishing between lipid-poor angiomyolipoma (AML) and renal cell carcinoma, and to determine whether it improves the detection of lipid-poor AML when added to the angular interface sign. The results showed that both OBS and angular interface sign were strongly associated with AML and had high specificity in the lipid-poor population. Using both signs together increased the sensitivity of AML detection without significantly reducing specificity.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2023)

Article Multidisciplinary Sciences

Point of care parenchymal volume analyses to estimate split renal function and predict functional outcomes after radical nephrectomy

Nityam Rathi, Worapat Attawettayanon, Yosuke Yasuda, Kieran Lewis, Gustavo Roversi, Snehi Shah, Andrew Wood, Carlos Munoz-Lopez, Diego A. Palacios, Jianbo Li, Nour Abdallah, Jared P. Schober, Marshall Strother, Alexander Kutikov, Robert Uzzo, Christopher J. Weight, Mohamed Eltemamy, Venkatesh Krishnamurthi, Robert Abouassaly, Steven C. Campbell

Summary: Accurate prediction of NBGFR after RN is crucial for clinical management and patient counseling. Preoperative global GFR, SRF, and RFC are important factors for this prediction. In this study, the accuracy of three methods (NRS, software-derived PVA, and LWH measurements) for determining SRF and predicting NBGFR were compared. The results showed that software-derived PVA had the highest accuracy and precision in estimating SRF and predicting NBGFR.

SCIENTIFIC REPORTS (2023)

Article Urology & Nephrology

Real-time estimation of nephron activity with a linear measurement system (RENAL-MS) predicts postoperative estimated glomerular filtration rate

Jared P. Schober, Kevin B. Ginsburg, Alexander Kutikov, Eric Y. Cho, Matt Loecher, David Strauss, Alberto Andres Castro Bigalli, Elizabeth Handorf, Mengying Deng, Jordan Anaokar, David Y. T. Chen, Richard E. Greenberg, Marc C. Smaldone, Rosalia Viterbo, Andres F. Correa, Robert G. Uzzo, Marshall Strother

Summary: This study aimed to evaluate whether a simple point-of-care measurement system could be used to replace nuclear medicine renal scintigraphy (NMRS) in predicting estimated glomerular filtration rate (eGFR) after nephrectomy. The results showed that the point-of-care tool (RENAL-MS) performed equally well as NMRS in predicting postoperative eGFR and de novo Stage 3 chronic kidney disease (CKD), suggesting that NMRS may not be necessary in this setting.

BJU INTERNATIONAL (2023)

Article Urology & Nephrology

Diabetes, Obesity, and Pathological Upstaging in Renal Cell Carcinoma: Results From a Large Multi-institutional Consortium

Deepak K. Pruthi, Gregor Miller, Donna P. Ankerst, Matthias Neumair, Umberto Capitanio, Andres F. Correa, Brian R. Lane, Eduard Roussel, Thomas B. Mcgregor, Ithaar H. Derweesh, Mauricio Cordeiro, Phillip M. Pierorazio, Carlos Calvo, Hai Bi, Sabrina L. Noyes, Margaret Meagher, Alexander Kutikov, Robert G. Uzzo, Hendrik Van Poppel, Alessandro Larcher, Francesco Montorsi, Michael W. Kattan, Dharam Kaushik, Michael A. Liss

Summary: This study aimed to investigate whether clinical risk factors and morphometric features on preoperative imaging can predict pathological upstaging in cT1 renal cell carcinoma patients. Through a retrospective study, we found that increasing preoperative tumor size, increasing age, diabetes, higher BMI, and male sex were associated with pathological upstaging. Additionally, hilar tumors were more likely to be upstaged.

JOURNAL OF UROLOGY (2023)

Article Medicine, General & Internal

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

Christopher W. Ryan, Catherine M. Tangen, Elisabeth Heath, Mark N. Stein, Maxwell Meng, Ajjai S. Alva, Sumanta K. Pal, Igor Puzanov, Joseph Clark, Toni K. Choueiri, Neeraj Agarwal, Robert G. Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Ian M. Thompson Jr, Primo N. Lara Jr

Summary: Postoperative administration of everolimus did not show improvement in recurrence-free survival compared to placebo for renal cell carcinoma patients at high risk of recurrence after nephrectomy. These results do not provide support for the adjuvant use of everolimus in the treatment of renal cell carcinoma following surgery.

LANCET (2023)

Meeting Abstract Urology & Nephrology

IDENTIFICATION OF INTRATUMOR PATHOGENS FROM SINGLE-CELL RNA SEQUENCING, CELLULAR DYSFUNCTION AND IMMUNE RESPONSE

Laura Bukavina, Mohit Sindhani, Henkel Valentine, Daniel Ranti, Kirtishri Mishra, Alexander Kutikov, Shilpa Gupta, John Sfakianos, Mahmoud Ghannoum, Mauricio Retuerto, Andres Correa, Robert Uzzo, Philip Abbosh

JOURNAL OF UROLOGY (2023)

Meeting Abstract Urology & Nephrology

PARTIAL VERSUS RADICAL NEPHRECTOMY FOR COMPLEX RENAL MASS: MULTICENTER COMPARATIVE ANALYSIS OF FUNCTIONAL OUTCOMES (ROSULA COLLABORATIVE GROUP)

Clara Cerrato, Margaret F. Meagher, Riccardo Autorino, Giuseppe Simone, Bo Yang, Robert Uzzo, Francesco Porpiglia, Umberto Capitanio, James Porter, Alp T. Beksac, Mimi Nguyen, Savio D. Pandolfo, Kevin Hakimi, Luke Wang, Andrea Minervini, Clayton Lau, Monish Aron, Daniel Eun, Alexandre Mottrie, Carmen Mir, Chandru Sundaram, Alessandro Antonelli, Jihad Kaouk, Ithaar H. Derweesh

JOURNAL OF UROLOGY (2023)

Article Urology & Nephrology

Partial or radical nephrectomy for complex renal mass: a comparative analysis of oncological outcomes and complications from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group

Clara Cerrato, Devin Patel, Riccardo Autorino, Giuseppe Simone, Bo Yang, Robert Uzzo, Francesco Porpiglia, Umberto Capitanio, James Porter, Alp Tuna Beksac, Andrea Minervini, Alessandro Antonelli, Maria Angela Cerruto, Clayton Lau, Akbar Ashrafi, Daniel Eun, Alexandre Mottrie, Carmen Mir, Margaret F. Meagher, Dhruv Puri, Mimi Nguyen, Sohail Dhanji, Franklin Liu, Savio D. Pandolfo, Alexander Kutikov, Francesco Montorsi, Inderbir S. Gill, Chandru Sundaram, Jihad Kaouk, Ithaar H. Derweesh

Summary: This study compares the outcomes of robotic-assisted partial nephrectomy (RAPN) and minimally invasive radical nephrectomy (MIS-RN) for complex renal masses (CRM). The results indicate that RAPN is not associated with increased risk of complications or worsened oncological outcomes compared to MIS-RN, and may be preferred when clinically indicated.

WORLD JOURNAL OF UROLOGY (2023)

暂无数据